Work

Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

Year: 2016

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-016-3009-7

Authors: Muhammad R. Khawaja, Alpa M. Nick, Vinu Madhusudanannair, Siqing Fu, David Hong, Lacey M. McQuinn, Chaan S. Ng, Sarina A. Piha-Paul, Filip Janku, Vivek Subbiah, Apostolia Tsimberidou, Daniel Karp, Funda Meric-Bernstam, Karen H. Lu, Aung Naing

Institutions: The University of Texas MD Anderson Cancer Center, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G111615301, Cancer Center Support Grant

OpenAlex ID: W2308561945

FWCI: 1.956

Cites: 18

Cited by: 39

Related to: 10